Debate over details of US biosimilar pathway continues to rage

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fox, J. Debate over details of US biosimilar pathway continues to rage. Nat Biotechnol 30, 577 (2012) doi:10.1038/nbt0712-577

A Modified Drift Tube Ion Mobility-Mass Spectrometer for Charge-Multiplexed Collision-Induced Unfolding
- Daniel D. Vallejo
- , Daniel A. Polasky
- , Ruwan T. Kurulugama
- , Joseph D. Eschweiler
- , John C. Fjeldsted
- & Brandon T. Ruotolo
Analytical Chemistry (2019)
Fármacos biosimilares: un nuevo escenario en las terapias biológicas
- José M. Serra López-Matencio
- , Alberto Morell Baladrón
- & Santos Castañeda
Reumatología Clínica (2017)
Biosimilars: A New Scenario in Biologic Therapies
- José M. Serra López-Matencio
- , Alberto Morell Baladrón
- & Santos Castañeda
Reumatología Clínica (English Edition) (2017)
The Tortoise and the Hare: Evolving Regulatory Landscapes for Biosimilars
- Chamindika S. Konara
- , Ross T. Barnard
- , Damian Hine
- , Evan Siegel
- & Vito Ferro
Trends in Biotechnology (2016)
Introduction of Biosimilar Therapeutics Into Nephrology Practice in the United States: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
- Jay B. Wish
- , Chaim Charytan
- , Glenn M. Chertow
- , Kamyar Kalantar-Zadeh
- , Alan S. Kliger
- , Robert J. Rubin
- , Jerry Yee
- & Steven Fishbane
American Journal of Kidney Diseases (2016)